Navigation Links
Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients
Date:5/12/2008

Meets MD's Treatment Need

BETHESDA, Md., May 12 /PRNewswire/ -- Naturlose, a natural sugar approved as a food ingredient in the U.S. and abroad, has been found to reduce the spikes of serum glucose that follow consumption of food (1). In a Phase 3 human clinical trial, Spherix (Nasdaq: SPEX) is currently studying the efficacy and safety of Naturlose for the treatment of diabetes. While the Phase 3 trial is ongoing, Spherix has engaged market research companies to seek feedback as to the likelihood of Naturlose market acceptance assuming successful completion of the Phase 3 trials and ultimate FDA approval.

Focus group testing with diabetes patients and physicians who treat diabetes has identified a clear role for Naturlose in the management of diabetes. A series of focus group meetings were held in two U.S. cities. The testing included demographically diverse groups of both general practitioners and endocrinologists, as well as patients ranging from the age of 30 to 70.

Patients, many of whom suffer side effects from current oral diabetes medications, valued the safety of a natural product already approved for use in food. Patients expressed a preference for the soft chewable formulation, with the fast-dissolving oral and powdered forms ranking second and third, respectively. The convenience of meal-time dosing was also mentioned by patients. Patients expressed a clear need for more information about diabetes. Many feared the long-term consequences of poor long-term control of blood glucose and were eager to have practical advice on improving their health.

Physicians, who treat diabetes with multiple drugs, each acting at a different biochemical point to control blood sugar, were intrigued by Naturlose's novel mechanism of action. For physicians, drug choice was a complex algorithm involving level of glucose control, tolerance to side effects, cost, and patient compliance. The consensus of the physicians was that with three of four of the most widely prescribed drugs to treat type 2 diabetes, patient toleration of side effects limited their ability to achieve the glycemic control that they seek for their patients. Physicians expressed significant frustration with the ability of current medications to control patients' blood sugar to guideline-based goals, and saw value in being able to add a safe new therapeutic approach to their arsenal.

Both patients and physicians expressed interest in the safety and efficacy data currently being developed for Naturlose in the Phase 3 trial. Because Naturlose is approved as a food ingredient and the food-grade sugar is available, both patients and physicians had the opportunity to taste Naturlose during the focus group meetings. The sweet flavor had great appeal. After tasting Naturlose one general practitioner remarked, "We are all going to start taking it."

Data from the national prescription audit of the diabetes category for 2007 revealed 167,019,000 total prescriptions, with 58,015,000 new prescriptions. The diabetes category remained very active in 2007. Price level and positioning on insurer and managed care formularies are important issues that manufacturers continuously address. Regardless of product launch date, the share of new prescriptions remains around 30%. More recent brand product launches with the largest marketing budgets show a higher share of new prescriptions. However, generics with recent launches are also showing year-to-year prescription growth. As a result, significant opportunities exist for Spherix over the next several years.

1. Yongming Lu, Gilbert Levin, Thomas Donner. Tagatose, a New

Anti-Diabetic and Obesity-Control Drug. Diabetes, Obesity and

Metabolism. 10, 2008, 109-134.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Spherix's Internet address is http://www.spherix.com.


'/>"/>
SOURCE Spherix
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AHIP Statement on CMS Proposed Medicare Marketing Regulations
2. Conseco Reaches Settlement of Multistate Market Conduct Examination
3. Self-Medication One of Many Factors Driving OTC Drug Market Past $80 Billion by 2012
4. Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)
5. Cadient Group Continues Winning Streak; Receives Multiple Honors at 2008 Pharmaceutical Advertising and Marketing Excellence Awards
6. Triple-S Management Corporation Reports First Quarter 2008 Results; Cites Growth Resulting From Strong Market Position
7. Customer Communications Group Selected by The Childrens Hospital for Direct Marketing Expertise
8. Strategies for Winning Clinical Investigators in a Competitive Marketplace
9. Marketing Executives Finding Value in Best Practice Database
10. David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida
11. Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, ... announce an upgrade to the company's Yelp listing. Bay Area residents struggling from ... diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, ... the 7th Edition of International Social Design Awards. , The 7th A' ... System Designers, Governments and Institutions worldwide with realized projects and conceptual works. , ...
(Date:2/26/2017)... New York, New York (PRWEB) , ... February ... ... of luxury baby products for wholesale distribution in North America, today announced it ... established online sites. The company, which prides itself on crafting quality and unique ...
(Date:2/26/2017)... ... ... ODH, Inc.™ announced today it will exhibit and speak at the ... in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present on ... health management. , ODH will also have an exhibit booth where attendees may speak ...
(Date:2/25/2017)... ... ... FCPX users now have the ability to sharpen a desired color range ... have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, and ... can visually see the color range effected with ease all within Final Cut ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) today announced ... Raymond James and Associates, 38 th ... in Orlando, FL. Cowen and ... on March 7, 2017 in Boston, MA. ... 2017 in Miami, FL. ...
(Date:2/27/2017)... Leading Countries, Technologies and Companies The ... a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from ... 9.1% from 2016 to 2027. The market is estimated at $816m ... ... on to discover how you can exploit the future business opportunities ...
(Date:2/27/2017)... October – December 2016 Revenues amounted to SEK 0.3 ... Result after tax amounted to SEK -16.3 (-6.5) million, corresponding ... Cash flow from operating activities amounted to SEK -8.3 (-7.3) million ... Period full year 2016 ... amounted to SEK -39.5 (-29.5) million Result after tax amounted ...
Breaking Medicine Technology: